Key Takeaways Tempus AI expands 2026 footprint via collaborations across pharma, healthcare, and tech sectors. TEM partners with Daiichi Sankyo to advance oncology ADC program using PRISM2 AI models. Tempus AI integrates Median tech and teams up with NYU Langone to enhance diagnostics and cancer care. Tempus AI (TEM) continues to expand its footprint in 2026 through a series of strategic collaborations. By partnering with leading pharmaceutical companies, healthcare institutions, and technology innovators, ...